Vaccines

September 20, 2024

VUMC method tracks down rare, broadly reacting antibodies: study

The discovery, reported in the journal PLOS Pathogens, could help open the door to the development of effective vaccines and antibody therapies with an “exceptional breadth of pathogen coverage.”

By Bill Snyder
September 19, 2024

Fight the flu with Flulapalooza; annual event is set for Wed., Sept. 25; shots available at regional hospitals as well at other dates and times

Flulapalooza will happen at the tent between Light Hall and the VA Hospital from 6 a.m. – 6 p.m. Enter through Light Hall, North Lobby. Stop by to get your flu shot, reconnect with fellow colleagues, and interact with your favorite Nashville mascots.

(iStock)
September 13, 2024

VUMC joins national effort to prevent another pandemic

Developed in the wake of the COVID-19 pandemic, ReVAMPP will support a coordinating center and seven research centers, including VUMC, with a focus on nine virus groups that pose the greatest risk to human health.

By Bill Snyder
September 4, 2024

RSV vaccine in older people cuts risk of hospitalization

A multicenter study conducted in 19 states between October 2023 and March 2024 demonstrated that RSV vaccination was 75% effective in preventing RSV-associated hospitalizations for adults age 60 and older.

By Bill Snyder
(iStock)
August 13, 2024

VUMC, DOD join forces for a hantavirus antibody “sprint”

VUMC’s antibody collaboration with the DOD goes back to 2018, when the medical center signed a five-year cooperative agreement with the U.S. Defense Advanced Research Projects Agency to develop protective treatments that can be rushed to health care providers within weeks after a viral outbreak.

By Bill Snyder
July 12, 2024

Wesley Self named to leadership role in global clinical trials network

The Strategies and Treatments for Respiratory Infections and Viral Emergencies network includes more than 300 sites around the world and international experts in clinical trials, infectious diseases, critical care and pandemic preparedness.

By Bill Snyder
June 28, 2024

Antibody trial launched to address enterovirus threat

Enterovirus D68 has caused an increasing number of infections during the past decade and is associated with acute flaccid myelitis, a polio-like condition that mostly affects children and causes sudden weakness and paralysis.
By Bill Snyder
June 12, 2024

Scientists find antibodies that block parainfluenza virus infection

The antibodies may have clinical benefit as antiviral drugs to treat potentially life-threatening infections in elderly and immunosuppressed patients.
By Bill Snyder
May 31, 2024

Antibodies may aid effort to fight influenza B: study

The findings reported in the journal Immunity support the development of a monoclonal antibody for prevention and treatment of influenza B — and will help guide efforts to develop a universal influenza vaccine.
By Bill Snyder
April 3, 2024

Talbot leads US immunization committee

Infectious diseases researcher H. Keipp Talbot, MD, MPH, has been appointed chair of the Advisory Committee on Immunization Practices of the U.S. Centers for Disease Control and Prevention.
By Paul Govern
March 14, 2024

Immune cell profiles may guide flu vaccine timing in pediatric stem cell transplant patients

A new study led by Vanderbilt University Medical Center researchers has identified key immune cell populations that predict how well pediatric hematopoietic stem cell transplant (HCT) recipients will respond to the influenza vaccine.
By Paul Govern
January 17, 2024

Bird flu vaccine more effective with potent adjuvant

The avian (bird) influenza vaccine creates a more robust immune response when paired with a potent ingredient known as an adjuvant, according to Vanderbilt research published in The Journal of Infectious Diseases.
By Craig Boerner
November 6, 2023

Children’s antibodies highly potent against COVID-19: study

Reporting Nov. 6 in Cell Reports Medicine, Ivelin Georgiev, PhD, and colleagues demonstrated that antibodies isolated from children’s blood samples displayed high levels of neutralization and potency against variants of the COVID-19 virus, SARS-CoV-2, even when the children had not previously been exposed to or vaccinated against those variants.
By Bill Snyder
1 2 3 … 14